Compare Philip Morris International Inc. (PM) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs Rocket Lab USA Inc — how do they compare? Philip Morris International Inc. trades at $200.2 (market cap $312.50B), while Rocket Lab USA Inc trades at $67.5 (market cap $43.74B). The key difference: Philip Morris International Inc. is far larger — about 7.1× Rocket Lab USA Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Philip Morris International Inc. for 85 Days and Rocket Lab USA Inc for 29 Days on average.
| PM | RKLB | |
|---|---|---|
Market Cap | $312.50B | $43.74B |
Volume | 5,517,172 | 22,892,581 |
Sector | Consumer Staples | Industrials |
52-Week High | $200.50 | $150.23 |
52-Week Low | $144.33 | $39.48 |
Typical Hold Time | 85 Days | 29 Days |
Enterprise Value | $355.62B | $41.57B |
Dividend Yield | 3.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Rocket Lab (RKLB) trades at $67.47, down 6.19% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of -$198.21M in 2025, though revenue grew to $601.80M. Recent news highlights a record 20-launch deal with Synspective, expanding the backlog past 100 missions, providing a positive catalyst amid ongoing losses and high valuation multiples.
The outlook remains speculative; strong analyst consensus (76% buy ratings) and a $107 price target suggest long-term growth potential from launch demand, but profitability challenges, cash burn, and competitive pressure from SpaceX pose significant risks. Investment hinges on execution toward Neutron rocket commercialization and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
